Sign up for news updates

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Evolving Standards of Care

Add ILCN as a preferred source
  • Novel Targets and Therapies: KEAP1- and NFE2L2-Mutant Squamous Cell Lung Cancer

    Novel Targets and Therapies: KEAP1- and NFE2L2-Mutant Squamous Cell Lung Cancer

    Paul Paik, MD, et al.
    Evolving Standards of Care

    During an interview with ILCN, Drs. Paul Paik and Jonathan Reiss discuss the implications of KEAP1 and NFE2L2 mutations in NSCLC.

  • Role of Liquid Biopsy in the Clinic Growing

    Role of Liquid Biopsy in the Clinic Growing

    Leah Lawrence
    Early Detection & Screening, Evolving Standards of Care

    Lung cancer specialists are slowly being faced with the challenge of how to balance the benefits of next-generation tumor tissue testing against those of liquid biopsy in the clinic. During the 2021 International Society of Liquid Biopsy (ISLB) Congress, Natasha Leighl, MD, of Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada, provided attendees with…

  • Multidisciplinary Tumor Boards: Six Eyes See More than Two

    Multidisciplinary Tumor Boards: Six Eyes See More than Two

    Mihaela Aldea, MD, PhD, et al.
    Evolving Standards of Care

    See how specialists in France use MTBs to develop the most beneficial treatment strategies for patients and to decrease inequity in cancer care.

  • Unplanned Hospital Care in Patients With NSCLC

    Unplanned Hospital Care in Patients With NSCLC

    Manan P. Shah, MD, et al.
    Evolving Standards of Care

    Study findings suggest that a significant number of unplanned hospital visits for patients with lung cancer might be avoidable.

  • Predicting Early Weight Loss in Radiotherapy

    Predicting Early Weight Loss in Radiotherapy

    Dirk De Ruysscher, MD, PhD
    Evolving Standards of Care

    Study shows emerging techniques may improve prognostic and predictive models in identifying patients at risk for early weight loss.

  • In Brief for February 9, 2022

    In Brief for February 9, 2022

    John Austin
    Evolving Standards of Care, Meeting News, Names & News

    TTLC goes virtual. Positive results reported for pembrolizumab. GO2 Foundation names Chief of Healthcare Delivery.

  • The Art and Science of Patient–Doctor Communication

    The Art and Science of Patient–Doctor Communication

    Corey J. Langer, MD, FACP, et al.
    Evolving Standards of Care, Patient Advocacy

    When facing a grave illness, especially for the first time, many people are worried, frightened, and overwhelmed. They may have difficulty focusing their attention on daily tasks and experience skewed perceptions and memories based on intense emotions. This distress can also adversely affect the course and severity of disease and the success of its treatment.…

  • Multifaceted Initiative Launches Aimed at Reducing Lung Cancer Deaths 25% by 2030

    Multifaceted Initiative Launches Aimed at Reducing Lung Cancer Deaths 25% by 2030

    Evolving Standards of Care

    The Baptist Cancer Center in Memphis, Tennessee, has launched a new initiative that comprises seven components that will address prevention, diagnosis, and treatment of lung cancer through smoking cessation, low-dose CT screening, algorithmic management of incidentally detected lung nodules, multidisciplinary decision-making and care, high-quality surgical care, high-quality pathologic evaluation (including biomarker testing), and expanded access…

  • COVID-19 and Lung Cancer

    COVID-19 and Lung Cancer

    Lauren C. Shapiro, et al.
    Evolving Standards of Care

    Data from multiple groups1,2 have shown the significant impact of COVID-19 infection among patients with malignancies, leading to high overall morbidity and mortality; this includes our own institution,3 which saw numerous cases of COVID-19 very early in the pandemic. Lung cancer stood out as the cancer (along with hematological malignancies) most significantly impacted by this…

  • Pembrolizumab Plus Platinum-Doublet Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Unresectable, Locally Advanced Stage III NSCLC: The KEYNOTE-799 Trial in Perspective

    Pembrolizumab Plus Platinum-Doublet Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Unresectable, Locally Advanced Stage III NSCLC: The KEYNOTE-799 Trial in Perspective

    Noemí Reguart, et al.
    Evolving Standards of Care

    Approximately one-third of patients with NSCLC are diagnosed with unresectable, locally advanced (LA) stage III disease.1 Historically, the standard of care for these patients has been concurrent platinum-based chemotherapy with definitive thoracic radiation therapy (cCRT), 2 garnering a median OS of approximately 28 months and 5-year OS rates of 15% to 30%, at best. The…

View ILCN Archives

Provider Resources

Popular Articles